Discovery and development of a novel N-(3-bromophenyl)-{[(phenylcarbamoyl)amino]methyl}-N-hydroxythiophene-2-carboximidamide indoleamine 2,3-dioxygenase inhibitor using knowledge-based drug design

Teng-Kuang Yeh,Jen-Shin Song,Po-Wei Chang,Jin-Chen Yu,Chia-Hwa Chang,Fang-Yu Liao,Ya-Wen Tien,Ramajayam Kuppusamy,An-Siou Li,Chi-Han Chen,Chieh-Wen Chen,Li-Mei Lin,Hsin-Huei Chang,Chih-Hsiang Huang,Jau-Ying Yao,Mine-Hsine Wu,Yi-Hui Peng,Ching-Cheng Hsueh,Wen-Chi Hsiao,Pei-Husan Chen,Chin-Yu Lin,Su-Huei Hsieh,Chuan Shih,Ming-Shiu Hung,Su-Ying Wu,Ching-Chuan Kuo,Shau-Hua Ueng
DOI: https://doi.org/10.1016/j.ejmech.2021.114043
IF: 7.088
2022-02-01
European Journal of Medicinal Chemistry
Abstract:Indoleamine 2,3-dioxygenase-1 (IDO1) is a potential target for the next generation of cancer immunotherapies. We describe the development of two series of IDO1 inhibitors incorporating a N-hydroxy-thiophene-carboximidamide core generated by knowledge-based drug design. Structural modifications to improve the cellular activity and pharmacokinetic (PK) properties of the compounds synthesized, including extension of the side chain of the N-hydroxythiophene-2-carboximidamide core, resulted in compound 27a, a potent IDO1 inhibitor which demonstrated significant (51%) in vivo target inhibition on IDO1 in a human SK-OV-3 ovarian xenograft tumor mouse model. This strategy is expected to be applicable to the discovery of additional IDO1 inhibitors for the treatment of other diseases susceptible to modulation of IDO1.
chemistry, medicinal
What problem does this paper attempt to address?